Increased thromboxane B2 excretion in diabetes mellitus

Area of Science:

• Biochemistry
• Nephrology
• Endocrinology

Background:

• Thromboxane A2 (TXA2) is a key mediator in platelet aggregation and vasoconstriction.
• Diabetes mellitus is associated with increased TXA2 production and decreased prostacyclin formation.
• The specific role of renal TXA2 in diabetic nephropathy requires further elucidation.

Purpose of the Study:

• To establish a simplified method for quantifying urinary TXB2 (UTXB2).
• To investigate the contribution of renal TXA2 to overall UTXB2 excretion.
• To explore the pathophysiologic role of renal TXA2 in diabetic nephropathy.

Main Methods:

• Developed a one-step extraction method for UTXB2 using an octadecylsilyl-silica column.
• Validated the extraction method for radioimmunoassay, assessing recovery and parallelism.
• Administered aspirin to suppress platelet TXA2 synthesis to assess renal TXA2 contribution.
• Measured UTXB2 excretion in healthy controls and patients with diabetes, correlating with proteinuria and renal function parameters.

Main Results:

• The one-step extraction method proved efficient and accurate for UTXB2 measurement.
• Aspirin administration significantly reduced UTXB2 excretion, indicating substantial renal TXA2 contribution.
• Patients with diabetes exhibited higher UTXB2 levels compared to controls.
• Elevated UTXB2 levels were particularly pronounced in diabetic patients with significant proteinuria (>100 mg/day).
• UTXB2 excretion correlated negatively with p-aminohippuric acid clearance but not creatinine clearance.

Conclusions:

• Renal TXA2 synthesis is significantly elevated in patients with diabetic nephropathy.
• Augmented renal TXA2 may contribute to the pathophysiology of diabetic kidney disease.
• Renal TXA2 may play a role in altered renal hemodynamics and increased proteinuria in diabetes.